BCL2 and glioblastoma: NVP-AUY922 enhances the efficacy of (1) radiotherapy in lung cancer[25], glioblastoma cancer stem cell-like cells[26]; (2) Bcl-2 inhibitor ABT-737 in small cell lung cancer[27]; (3) PI3K inhibitor omipalisib (GSK458)[28]; MEK inhibitor trametinib[29] in non-small cell lung cancer (NSCLC); (4) cytarabine in acute myeloid leukemia (AML) cells[30]; and (5) heating therapy in colon cancer cells[31].